Factors such as increase in awareness of hepatitis B infection prevention, governments have mandated the immunization and hepatitis B vaccine included in national immunization schedule in many countries driving the market growth of hepatitis B vaccine globally.

The report titled “Hepatitis B Vaccine Market - Growth, Future Prospects and Competitive Analysis, 2017–2025” offers strategic insights into the overall hepatitis B vaccine market along with the market size and estimates for the duration 2015 to 2025. The research study covers in-depth analysis of market segments based on composition, end users age and different geographical regions.

In order to help strategic decision makers, the report also includes competitive profiling of the leading players in global hepatitis B vaccine market, attractive investment proposition and market positioning of key manufacturers sections. Other in-depth analysis provided in the report includes:

Geographically, the global hepatitis B vaccine market is studied for the following regional markets:   

• North America
  • U.S.
  • Canada
• Europe
  • U.K
  • Germany
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • Rest of Asia Pacific
• Latin America
• Middle East and Africa

Market size and forecast for these regional and country level markets are presented in this study for the period 2015-2025. Market growth rates for the forecast period 2017-2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global hepatitis B vaccine market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global hepatitis B vaccine market. This report concludes with company profiles section that highlights major information about the key players engaged in global hepatitis B vaccine market. In-depth competitive environment analysis and historical years (2015) market size data are also provided in the report.      

Thus, the research study provides a holistic view of the global hepatitis B vaccine market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.

Based on composition, the global hepatitis B vaccine market is segmented as follows:  

• Mono Vaccines
• Combination Vaccines

Hepatitis B is a life threatening liver infection caused by the hepatitis B virus. Vaccine is most effective than any other treatment in preventing infection. According to WHO (world health organization), prevalence of hepatitis B is highest in Western Pacific and African region however, lowest in American population. Factors such as an increase in awareness of vaccines are expected to contribute the market growth of hepatitis B vaccine globally. For the purpose of study market is segmented on the basis of composition of vaccine such as mono and combination vaccine. Combination vaccines that protect against multiple pathogens, it involves combination of multiple antigens into a single vaccine. Combination vaccine such as Infanrix Hexa, Hexaci ma/Hexyon, Twinrix, Ambirix, Comvax widely used for the prevention of hepatitis B infection. It is observed that, combination vaccine is major revenue generating segment. Factors such as higher patient compliance, reduced number of dose frequency, better disease control, coverage of vaccine under national immunization program and reduced chances of missing immunization are driving the growth of combination vaccine market globally. It is observed that mono vaccines such as Recombi vax HB, Fendrix and Engeri x-B are approved for the treatment of hepatitis B infection.

Based on end user age group, the global hepatitis B vaccine market is segmented as follows:  

• Adult Hepatitis B Vaccines
• Pediatric Hepatitis B Vaccines

Hepatitis B virus cause life threatening liver disease, vaccine is more effective than any other treatment in preventing infection. The choice of hepatitis B vaccine varies with the age. Adult Hepatitis B Vaccines are used for active immunization of individuals aged above 18 and 21 in Europe and US respectively. Hepatitis B is one of the most common travelers diseases which can be avoided by vaccine immunization. Governments across the world have mandated the immunization of travelers, which is acting as a growth driver for the hepatitis B vaccines market across the world. It is observed that in base 2016, adult hepatitis B vaccines held largest market share as adults have high risk of developing hepatitis B infections due to end-stage renal disease, drug abuse and HIV infection which is driving the market growth of adult hepatitis B vaccines globally. In terms of immunogenicity, pediatric vaccines differ from adult vaccines. Pediatric hepatitis B vaccines are used for the prevention of hepatitis B infection in infants, toddlers, and adolescents because babies and young children are at higher risk for developing the potentially fatal complications of the infection. It is estimated that pediatric hepatitis B vaccines will show steady growth rate during forecast period. It is observed that pediatric vaccines such Infanrix, hexa, Hexacima/Hexyon, Ambirix, and Comvax. Infanrix hexa are widely accepted in market.

For the purpose of this study, the hepatitis B vaccine market is categorized into:

• North America
• Europe
• Asia Pacific
• Latin America (LATAM)
• Middle East and Africa (MEA)

Hepatitis B is life threatening liver disease that can cause acute and chronic liver infection and may lead to cirrhosis and liver cancer. Safe and effective vaccines are available in market to prevent hepatitis B infection. According to World Health Organization (WHO) prevalence of hepatitis B is highest in Western Pacific and in African region more than 6% of the adult population is affected with hepatitis B infection. In South East Asia and European region, it is estimated that 2% and 1.6% of the general population is affected with hepatitis B, respectively. The burden of hepatitis B infection is considerably less in the American population which is approximately 0.7% of the overall population. It is observed that in the base year 2016, North America was major revenue contributing segment. Factors such as higher cost of vaccines, immunization programs and favorable R&D activities driving the market growth in North America. Currently, Asia Pacific is not major revenue generating segment but it is estimated that it will show highest CAGR during forecast period. Rising healthcare awareness, populous countries, increase in awareness of vaccines, government initiative in vaccination program would influence the growth of hepatitis B vaccine market in Asia Pacific region.